Document Detail


The future of thrombolysis in the treatment of acute myocardial infarction.
MedLine Citation:
PMID:  11824005     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The ability of thrombolytic therapy to lower mortality in patients with acute myocardial infarction was first demonstrated in 1986 by the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. In the ensuing 10 years, large efforts have been undertaken to develop more effective and safer thrombolytic agents. In addition, the value of adjunctive agents influencing thrombotic and thrombolytic processes was demonstrated, and newer agents are under active investigation. This review focuses on theoretical and practical aspects of optimizing thrombolytic therapy and on genetically engineered third generation plasminogen activators. Optimized thrombolytic therapy may make this form of therapy available to patients who are currently considered ineligible, and it will lead to earlier, more complete reperfusion of infarct-related coronary arteries. The benefits and risks of optimized thrombolytic regimens relative to those of mechanical reperfusion strategies will require constant reassessment while both forms of treatment develop.
Authors:
C Bode; M S Runge; R W Smalling
Related Documents :
16683215 - The effect of high plasma levels of angiotensin-converting enzyme (ace) and plasminogen...
7606305 - A population-based assessment of the use and effectiveness of thrombolytic therapy. the...
12652145 - Age-specific differences in the use of thrombolytic therapy and hospital outcomes in pa...
6608325 - Coronary artery bypass surgery following thrombolytic therapy for acute coronary thromb...
24315785 - Dynamic patterns of ventricular remodeling and apoptosis in hearts unloaded by heteroto...
891095 - Effects of actodigin on the heart.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European heart journal     Volume:  17 Suppl E     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1996 Sep 
Date Detail:
Created Date:  2002-02-04     Completed Date:  2002-02-14     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  55-60     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Medical Clinic III, University of Heidelberg, Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Fibrinolytic Agents / therapeutic use*
Humans
Myocardial Infarction / drug therapy*,  mortality
Myocardial Reperfusion / trends*
Tissue Plasminogen Activator / therapeutic use*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thrombolysis and mechanical intervention following myocardial infarction.
Next Document:  Perspectives gained from large-scale thrombolytic comparative trials.